Global Autosomal Recessive Familial Adenomatous Polyposis Drugs Market Industry Insights, Size, Share, Growth and Forecast to 2030
Research Nester published a report titled “Autosomal Recessive Familial Adenomatous Polyposis Drugs Market: Global Demand Analysis & Opportunity Outlook 2030” which delivers detailed overview of the global autosomal recessive familial adenomatous polyposis drugs market in terms of market segmentation by polyps site, treatment, distribution channel, and by region.
Further, for the in-depth analysis, the
report encompasses the industry growth indicators, restraints, supply and
demand risk, along with detailed discussion on current and future market trends
that are associated with the growth of the market.
The global
autosomal recessive familial adenomatous
polyposis drugs market is anticipated to attain a
significant CAGR over the forecast period, i.e., 2021–2030. On the basis of
treatment, the market is segmented into colectomy,
genetic counselling, medication, surgery, and others, out of which, the surgery
segment is anticipated to gain the leading share over the forecast period. This
can be attributed to the high success rate of surgery in removing benign
polyps. Furthermore, the easy availability, and faster results from this
method, are estimated to boost the segment growth. On the basis of distribution channel, the market is
segmented into hospitals, specialty clinics, and others, out of which, the
hospital segment is estimated to attain notable growth on the back of
increasing patient pool and presence of various specialists for consultation.
The market growth can be attributed to the increasing awareness among
masses about colorectal cancer, along with its growing incidences. As per
the data by the World Health Organization (WHO),
colorectal cancer is the third most deadly cancer, causing over 935,000 deaths
in 2020. Moreover, the growing cases of genetic
mutation in the MUTYH gene, which is caused when both parents have
altered gene, is estimated to boost the market growth. Additionally, increasing
investment in medical R&D activities for development of new drugs, is
estimated to boost the market growth.
Regionally,
the global autosomal recessive familial adenomatous polyposis drugs market is
segmented into five major regions including North America, Europe, Asia Pacific,
Latin America and Middle East & Africa region. The market in the North
America is anticipated to hold the largest share over the forecast period owing
to the high government funding and investment in the medical R&D activities,
backed by growing demand for effective treatment methods to treat autosomal
recessive familial adenomatous polyposis. Moreover, presence of major
pharmaceutical companies in the region, along with advanced healthcare sector
and increasing healthcare expenditure is estimated to boost the growth of the
regional market. As per the statistics by the World Bank, 16.416 % of the
GDP of North America was used for expanding the healthcare sector, in the year
2018. The market in the Asia Pacific region is
foreseen to gain the highest CAGR over the forecast period owing to the rising
patient pool of colorectal diseases, backed by increasing geriatric population
in countries, such as, India, and China. Moreover, growing healthcare
infrastructure, supported by the economic development is estimated to further
boost the market growth.
To understand key trends/future scope, download sample report
@ https://www.researchnester.com/sample-request-3097
Increasing Awareness Regarding Colorectal
Cancer to boost the Market Growth
Autosomal recessive familial adenomatous
polyposis or autosomal recessive FAP creates hundreds of polyps in the
intestinal and rectum area, which can also spread to stomach, liver and even
thyroid. These polyps can be malignant or benign, which however, turn into
cancerous tumors after 40 years of age. The chance of colorectal cancer is 100%
for an individual suffering with autosomal recessive FAP. The increasing
awareness about the treatment of colorectal cancer, is estimated to boost the
market growth.
However, high costs of drugs are expected
to operate as key restraint to the growth of the market over the forecast
period.
This report also provides the existing
competitive scenario of some of the key players of the global autosomal recessive familial adenomatous polyposis
drugs market which
includes company profiling of Bayer AG, Astellas Pharma Inc., Novartis AG,
Pfizer Inc., Genentech, Inc., Ipsen Biopharmaceuticals, Inc., Regeneron
Pharmaceuticals Inc., Eli Lilly and Company, Teva Pharmaceutical Industries
Ltd., and Bristol-Myers Squibb Company. The profiling enfolds key information
of the companies which encompasses business overview, products and services,
key financials and recent news and developments. On the whole, the report
depicts detailed overview of the global
autosomal recessive familial adenomatous polyposis drugs market that will help industry consultants,
equipment manufacturers, existing players searching for expansion
opportunities, new players searching possibilities and other stakeholders to
align their market centric strategies according to the ongoing and expected
trends in the future.
Curious about this latest version of report? Obtain Report Details
@ https://www.researchnester.com/sample-request-3097
About Research Nester
Research Nester
is a leading service provider for strategic market research and consulting. We
aim to provide unbiased, unparalleled market insights and industry analysis to
help industries, conglomerates and executives to take wise decisions for their
future marketing strategy, expansion and investment etc. We believe every
business can expand to its new horizon, provided a right guidance at a right
time is available through strategic minds. Our out of box thinking helps our
clients to take wise decision in order to avoid future uncertainties.
Contact for more Info:
AJ
Daniel
Email: info@researchnester.com
U.S.
Phone: +1 646 586 9123
U.K.
Phone: +44 203 608 5919
Comments
Post a Comment